Biological treatments and connective tissue disease associated interstitial lung disease

Current Opinion in Pulmonary Medicine

Volumn 17, Issue 5, 2011, Pages 362-367

  Panopoulos, Stylianos T ^a   Sfikakis, Petros P ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Biological treatments; connective tissue disease; interstitial lung disease; pulmonary fibrosis

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

BIOLOGICAL THERAPY; CLINICAL PRACTICE; CONNECTIVE TISSUE DISEASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG WITHDRAWAL; FATALITY; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL LUNG DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LUNG FIBROSIS; LUNG TOXICITY; MORTALITY; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SPONDYLOARTHROPATHY; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

CONNECTIVE TISSUE DISEASES; HUMANS; LUNG DISEASES, INTERSTITIAL; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80051781646     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283483ea5     Document Type: Review

References (52)

1. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010;11:180-210.
2. Liossis SN, Sfikakis PP. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 2008;127:280-285.
3. Karampetsou MP, Liossis SN, Sfikakis PP. TNF-a antagonists beyond approved indications: stories of success and prospects for the future. QJM 2010;103:917-928.
4. Castelino FV, Varga J. Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther 2010;12:213. The interstitial lung disease is frequent and characterized by high mortality rates in patients with connective tissue diseases.
5. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809-1815.
6. Theiss AL, Simmons JG, Jobin C, Lund PK. Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem 2005;280:36099-36109. (Pubitemid 41633881)
7. Sullivan DE, Ferris M, Pociask D, Brody AR. Tumor necrosis factor-alpha induces transforming growth factor-beta1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am J Respir Cell Mol Biol 2005;32:342-349. (Pubitemid 40478310)
8. Miyazaki Y, Araki K, Vesin C, et al. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J Clin Invest 1995;96:250-259.
9. Chizzolini C. T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis. Curr Opin Rheumatol 2008;20:707-712.
10. Apostolaki M, Armaka M, Victoratos P, Kollias G. Cellular mechanisms of TNF function in models of inflammation and autoimmunity. Curr Dir Autoimmun 2010;11:1-26. A thorough review of the proinflammatory tissue damaging and immunomodulatory functions of TNF.
11. Antoniou KM, Mamoulaki M, Malagari K, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 2007;25:23-28. (Pubitemid 46477481)
12. Bargagli E, Galeazzi M, Rottoli P. Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis. Eur Respir J 2004;24:708. (Pubitemid 39406147)
13. Vassallo R, Matteson E, Thomas CF Jr. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumour necrosis factor-alpha inhibition. Chest 2002;122:1093-1096.
14. Schultz R, Mattila J, Gappa M, Verronen P. Development of progressive pulmonary interstitial and intra-alveolar cholesterol granulomas (PICG) associated with therapy-resistant chronic systemic juvenile arthritis (CJA). Pediatr Pulmonol 2001;32:397-402. (Pubitemid 33015657)
15. Bargagli E, Galeazzi M, Bellisai F, et al. Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration 2008;75:346-349. (Pubitemid 351450408)
16. Aringer M, Houssiau F, Gordon C, et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009;48:1451-1454.
17. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011 [Epub ahead of print]. Review of all cases that developed new onset or exacerbation of interstitial lung disease during treatment with anti-TNF agents or the B-cell depleting agent rituximab.
18. Mauviel A, Daireaux M, Redini F, et al. Tumor necrosis factor inhibits collagen and fibronectin synthesis in human dermal fibroblasts. FEBS Lett 1988;236:47-52.
19. Chizzolini C, Parel Y, De Luca C, et al. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum 2003;48:2593-2604. (Pubitemid 37129436)
20. Kouba DJ, Chung KY, Nishiyama T, et al. Nuclear factor-kappa B mediates TNF-alpha inhibitory effect on alpha 2 (I) collagen (COL1A2) gene transcription in human dermal fibroblasts. J Immunol 1999;162:4226-4234. (Pubitemid 29314811)
21. Kuroki M, Noguchi Y, Shimono M, et al. Repression of bleomycin-induced pneumopathy by TNF. J Immunol 2003;170:567-574. (Pubitemid 36026184)
22. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:189-194. (Pubitemid 351183307)
23. De Bandt M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by antitumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005;7:R545-R551.
24. Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol 2007;36:172-178. (Pubitemid 47174545)
25. Nouijai A, Mounach A, Ghozlani I, et al. Fibrosing alveolitis after treatement of rheumatoid arthritis by infliximab. Presse Med 2009;38:e17-20.
26. Horai Y, Miyamura T, Shimada K, et al. Eternacept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease. J Clin Pharm Ther 2010 [Epub ahead of print].
27. Yokoyama T, Yamamoto H, Fukushima T, et al. A case of etanercept-induced pneumonitis. Nihon Kokyuki Gakkai Zasshi 2009;47:870-874.
28. Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2011 [Epub ahead of print]. In this study, the prevalence of etanercept-induced interstitial lung disease among 13 94 patients seen in clinical practice was 0.6%.
29. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008;178:948-955.
30. Huggett MT, Armstrong R. Adalimumab-associated pulmonary fibrosis. Rheumatology (Oxford) 2006;45:1312-1313.
31. Schoe A, van der Laan-Baalbergen NE, Huizinga TW, et al. Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab. Arthritis Rheum 2006;55:157-159. (Pubitemid 43235143)
32. Yamazaki H, Isogai S, Sakurai T, Nagasaka K. A case of adalimumab-associated interstitial pneumonia with rheumatoid arthritis. Mod Rheumatol 2010;20:518-521.
33. Allanore Y, Devos-Francois G, Caramella C, et al. Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 2006;65:834-835. (Pubitemid 43799191)
34. Dascalu C, Mrejen-Shakin K, Bandagi S. Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis. J Clin Rheumatol 2010;16:172-174.
35. Cohen JV, Capell BC, Kinniry PA, Epstein AL. Rapidly fatal pulmonary fibrosis in a patient with psoriatic arthritis treated with adalimumab. J Rheumatol 2011;38:398-399.
36. McGonagle D, Tan AL, Madden J, et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford) 2008;47:552-553.
37. Yoo WH. Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. Rheumatol Int 2010 [Epub ahead of print].
38. Daoussis D, Liossis SN, Tsamandas AC, et al. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum 2010;40:127-136.
39. Efthimiou P, Kukar M, Hersh A. Rituximab and lupus interstitial lung disease: friend or foe? Int J Rheum Dis 2011;14:e3-e4.
40. Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010;49:271-280. The first open prospective study, investigating the efficacy of rituximab in eight patients with scleroderma interstitial lung disease compared with six patients receiving standard therapy, reported beneficial results.
41. Lafyatis R, O'Hara C, Feghali-Bostwick CA, Matteson E. B cell infiltration in systemic sclerosis associated interstitial lung disease. Arthritis Rheum 2007;56:3167-3168. (Pubitemid 47502765)
42. Kishi J, Nanki T, Watanabe K, et al. A case of rituximab-induced interstitial pneumonitis observed in systemic lupus erythematosus. Rheumatology (Oxford) 2009;48:447-448.
43. Soubrier M, Jeannin G, Kemeny JL, et al. Organizing pneumonia after rituximab therapy: two cases. Joint Bone Spine 2008;75:362-365.
44. Swords R, Power D, Fay M, et al. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol 2004;77:103-104. (Pubitemid 39108808)
45. Heresi GA, Farver CF, Stoller JK. Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature. Respiration 2008;76:449-453.
46. Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol 2007;82:916-919. (Pubitemid 47502698)
47. Lafyatis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009;60:578-583.
48. Smith V, Van Praet JT, Vandooren B, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010;69:193-197.
49. Bosello S, De Sanctis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow up open-label trial. Arthritis Res Ther 2010;12:R54. An observational study investigating the safety of rituximab and its efficacy on skin sclerosis in nine patients with SSc; during 3-years follow-up, pulmonary function remained stable.
50. Kawashiri SY, Kawakami A, Sakamoto N, et al. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol Int 2010 [Epub ahead of print]. This is the first report on exacerbation of preexisting interstitial lung disease after therapeutic IL-6 inhibition.
51. Sfikakis PP, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by anti-TNF therapy: a paradoxical adverse reaction. Arthr Rheum 2005;52:2513-2518. (Pubitemid 41117439)
52. Dixon WAG, Hirsch KILL, Watson KID, et al., British Society for Rheumatology Biologics Register. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010;69:1086-1091. ILD may occur in up to 3% of patients with rheumatoid arthritis during anti-TNF treatment.